Antimicrobial Activity of SCH 27899, Oligosaccharide Member of the Everninomycin Class with a Wide Gram-Positive Spectrum  by Jones, Ronald N. & Barrett, Mary S.
ORIGINAL ARTICLE 
Antimicrobial Activity of SCH 27899, 
Oligosaccharide Member of the Everninomycin 
Class with a Wide Gram-Positive Spectrum 
Ronald N .  Jones*, Mary S .  Barrett 
The in vitro antimicrobial activity of SCH 27899 (everninomycin), a novel oligosaccharide compound of the 
everninomycin class, was compared with vancomycin, chloramphenicol, clinafloxacin, teicoplanin and doxycycline 
against 428 clinical strains of bacteria. Everninomycin base exhibited the greatest antimicrobial activity compared to 
other formulations against all strains tested (MICgo: 0.25 p,g/ml) followed by clinafloxacin and teicoplanin (MICW: 0.5 
pg/ml), vancomycin (MICgo: 2 pg/ml), and doxycycline (MICgo: 16 Fg/ml). Everninomycin demonstrated the best activity 
against Streptococcus spp. (serogroups A, B, C, F, G) and Streptococcus pneurnoniae, and lower activity against 
coagulase-negative staphylococci (MIC90: 0.5 pg/ml). All enterococci had an everninomycin MIC of 0.5 pg/ml or less. 
Everninomycin had no measurable antimicrobial activity against gram-negative aerobic organisms except Flavo- 
bacterium meningosepticurn (MIC50: 2 pglml). Some everninomycin activity was observed against Clostridium spp., 
Peptostreptococcus spp., and the Prevotella bivius-disiens group. Everninomycin showed excellent activity (MIC90: 
0.25 pg/ml) against the fluoroquinolone-resistant strains and all gram-positive strains resistant to vancomycin (MICs 
I 4  pg/ml). The MBC/MIC ratios and killing curve data suggest that everninomycin is not uniformly or rapidly bactericidal. 
These in vitro data indicate that everninomycin could be useful against emerging gram-positive strains resistant to other 
contemporary antimicrobials. 
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Vancomycin has emerged as the dominant alternative 
therapy for serious infections caused by oxacillin- 
resistant staphylococci and any gram-positive infection 
observed in a patient with intolerance to p-lactams or 
macrolides. Furthermore, enterococci that are resistant 
to penicillins are often treated with vanco-mycin and 
an active aminoglycoside. Recently, these choices have 
been compromised by glycopeptide resistance among 
the Enterococcus spp. (1-6) and some coagulase-negative 
Staphylococcus spp. (7) The laboratory transmission 
of vancomycin resistance from an enterococcus to 
Staphylococcus aureus was successfully made by Nobel 
et a1 (5 ) . ,  demonstrating the potential threat of serious 
glycopeptide resistance among highly virulent gram- 
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positive species possessing co-resistances to other drugs 
active against gram-positive bacteria. 
With the Enterococcus spp. and staphylococci being 
among the most prevalent causes of nosocomial in- 
fections (1) and the rapidly increasing development 
of vanco-mycin-resistance among enterococci (4.4% 
to 7.3% from late 1992 to early 1993), alternative 
regimens must be developed from among existing drugs 
or from new drug discovery programs (1, 3, 4, 6). 
Teicoplanin appears usable against only a minority of 
the vancomycin refractory enterococci by in vitro 
results or clinical experience (3), and older drugs such 
as chloramphenicol and some tetracyclines have not 
been bactericidal. Furthermore, high-level resistance to 
aminoglycosides which negates the bactericidal com- 
bination therapy with cell-wall active drugs (2), has 
also increased in many geographic areas of the United 
States (2,4). Clearly, new compounds should be ex- 
plored for broad, hopefully bactericidal action against 
these emerging gram-positive pathogens. 
Everninomycins are a complex of related anti- 
microbial substances that were initially evaluated nearly 
thirty years ago (8-10). Reports of good antimicrobial 
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activity against gram-positive bacteria were documented 
in the microbiology literature (8-10). Numerous modi- 
fications in the chemical structure have been evaluated 
in order to improve the pharmacokinetic properties 
such as intramuscular or oral absorptionas well as 
some physico-chemical characteristics (8). However, 
the further development of drugs in this class was 
initially abandoned because of a limited clinical need 
in an era of susceptibility to penicillinase-resistant 
penicillins, macrolides, tetracyclines, cephalo-sporins, 
and glycopeptides among gram-positive bacteria. 
In this study we report the in vitro evaluation of 
SCH 27899 (everninomycin), a novel oligosaccharide 
compound (Figure 1). Three formulations of evernino- 
mycin were studied: base, i.e. pure SCH 27899; 
N-methyl-glucamine (NMG) SCH 27899 prepared 
as a salt in a 1:3 molar ratio with NMG; and 
NMG complexed with hydroxypropyl-P-cyclodextrin 
Me OH 
0 r 
I 
OH 
Figure 1 Structure of SCH 27899. 
(HPPCD) SCH 27899 in a 1:3 to three molar ratio 
with NMG and HPPCD. We compare the 
antimicrobial activity of these formulations with 
vancomycin, teicoplanin, chloramphenicol, clinaflo- 
xacin (ll), and doxycycline against 428 clinical strains 
including selected sets of gram-positive bacteria that 
were resistant to glycopeptides, oxacillin, fluoroquin- 
olones and aminoglycosides. 
Materials and Methods 
Antimicrobial agents 
The laboratory standard drugs used in this study were 
obtained as follows: SCH 27899 (base; NMG; NMG, 
HPPCD) from Schering-Plough Research Institute 
(Kenilworth, NJ); vancomycin from Eli Lilly and Co. 
Research Laboratories (Indianapolis, IN); teicoplanin 
from Marion-Merrell Dow Pharmaceutical, Inc. 
(Kansas City, MO); chloramphenicol and clinafloxacin 
from Parke-Davis Pharmaceutical Research Division 
(Ann Arbor, MI); and doxycycline from Pfizer, Inc. 
(New York, NY). 
Bacterial strains 
All strains tested were recent clinical isolates pre- 
dominantly cultured from blood and other normally 
sterile body sites in patients at the University of Iowa 
Hospitals and Clinics (Iowa City, IA). The 392 gram- 
positive strains tested (listed in Table 2) are detailed for 
species and numbers in the table. A limited number 
of gram-negative aerobic bacteria (27 strains) and 
anaerobic bacteria (1 5 strains) were evaluated. Sixteen 
Staphylococcus spp. strains and eight enterococcal strains 
were selected and used to evaluate the effects of 
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Table 1 Comparative antimicrobial activity of 
everninomycin (SCH 27899) base, everninomycin 
N-methylglucamine (NMG), and everninomycin 
N-methylglucamine with hydroxypropyl-a-cyclodextrin 
(NMG, HPPCD) base, against 385 gram-positive strains. 
MBCs were determined for ten selected strains using 
NCCLS procedures (12, 14). The killing rate of ever- 
ninomycin base was determined for four strains at 
several concentrations. 
Everninomycin MlCyo  ( ,g /ml )  Results and Discussion 
Otganism (no. tested) Base NMC NMC, 
HPJCD 
Staphylococcus aureus 
oxacillin-resistant (25) 0.25 0.25 0.25 
oxacillin-susceptible (50) 0.25 0.25 0.25 
Staphylococcus epidermidis (25)" 0.5 0.5 0.5 
Staphylococcus huemolyticus 0.5 0.5 0.5 
Staphylococcus spp., 
Streptococcus spp., serogroup B (25) 0.12 0.12 0.12 
Enterococcusfaecium (30) 0.25 0.25 0.25 
Corynebacten'um jeikeitrm (1 1) 0.12 0.25 0.12 
Streptococcus spp. 
viridans group (25) 0.25 0.5 0.25 
serogroups C, F, and G (15) 0.12 0.25 0.12 
Streptococcus p y o p i e s  (25) 0.06 0.25 0.25 
Strepfococcus pneumoniae (54) 0.06 0.25 0.25 
a. Seventeen strains were oxacillin-resistant. 
b. Five strains were oxacillin-resistant. 
c. Fifteen strains were oxacillin-resistant. 
coagulase-negative (38)' 0.5 0.5 0.5 
Enterococcus spp. (20) 0.5 0.5 0.5 
Enterococcusfaecalis (32) 0.25 0.5 0.5 
changing conditions in the susceptibility test on the 
everninomycin MIC and to compare results between 
agar and broth MIC methods (Table 3 and 4). 
Furthermore, selected sets of fluoroquinolone-resistant 
(24 strains), gentamicin-resistant (5 1 strains), and 
vancomycin-resistant (56 strains) organisms were pro- 
cessed. Sixty-one strains of gram-positive bacteria with 
varying levels of vancomycin resistance (vanA, vunB, 
vanC) were also used in this study (Table 6). 
Susceptibility testing methods 
MICs were determined using cation-adjusted Mueller- 
Hinton (MH) broth and the microdilution method (12). 
Microdilution trays were manufactured by Prepared 
Media Laboratories (Tualatin, OR). Fastidious strains 
required the use of alternative agar dilution methods in 
order to determine MICs accurately (12). The 144 
strains of Streptococcus spp. were tested on MH agar 
supplemented with 5% sheep blood (SB) and incubated 
in a 5-7% COz atmosphere. The 15 strains of anaerobic 
organisms were evaluated using Brucella agar supple- 
mented with 5% SB (13). MICs were also determined 
after various changes in the standard NCCLS (National 
Committee for Clinical Laboratory Standards) pro- 
cedures such as changes in inoculum concentration, 
supplements, pH and type of incubation. MICs and 
The in vitro activities of SCH 27899 (everninomycin) 
comparing three preparations (base; NMG; NMG and 
HPPCD) against 385 gram-positive strains are listed in 
Table 1. Everninomycin NMG was two-fold less active 
(MICYO: 0.12 to 0.25 pg/ml) than either evernino- 
mycin base or everninomycin NMG, HPPCD when 
tested against Corynebacterium jeikeium, the viridans 
group Streptococcus and the serogroup C,F and G 
streptococci. Everninomycin NMG and evernino- 
mycin NMG, HPBCD were both four-fold less active 
than everninomycin base against Streptococcus pyogenes 
(serogroup A) and Streptococcus pneumoniae (MIC90: 0.06 
versus 0.25 p,g/ml). All other groups of organisms 
tested demonstrated equivalent susceptibility based on 
M I C ~ O  results for the three preparations. Evernino- 
mycin base was selected for further evaluation in this 
report as it displayed a slightly greater overall anti- 
microbial activity and spectrum among the three 
preparations evaluated. 
Table 2 displays the comparative antimicrobial 
activity of everninomycin base and five other anti- 
microbial agents tested against 392 gram-positive 
strains. Everninomycin base exhibited its strongest 
activity against Streptococcus spp. serogroups A,B,C,F,G 
and S. pneurnoniae (MIC90: 0.06 pg/ml). The lowest 
activity for everninomycin was observed against the 73 
coagulase-negative staphylococci (MIC90: 0.5 kg/ml). 
All staphylococci and Streptococcus spp. isolates had 
everninomycin MICs of 1 pg/ml or less. The entero- 
cocci generally had everninomycin MIC values 
distributed over a very narrow range (MICsos of 0.25 
pg/ml and MICyos of 0.25 to 0.5 kg/ml). All 
enterococci had MICs of I 0.5 p,g/ml. C. jeikeium 
and Bacillus cereus were also very susceptible to ever- 
ninomycin. The most active comparison drugs were 
clinafloxacin and teicoplanin. However, several entero- 
cocci were resistant to both drugs. 
The following is the rank order of antimicrobial 
activity (best-to-least) based on the MI& results of the 
compounds against all strains tested evernino-mycin 
(MICYO: 0.25 kg/ml) > clinafloxacin = teicoplanin 
(MICYO: 0.5 pg/ml) > vancomycin (MICY~: 2 pg/ml) 
> doxycycline (MICyo: 16 kg/ml). These data can be 
further placed in perspective with pharmacokinetic 
considerations by a ranking based on the proposed MIC 
breakpoint/MICyo ratio as follows: everninomycin 
base (4/0.25 p g / d  ratio = 16) = teicoplanin > 
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Table 2 Antimicrobial activity of everninomycin (SCH 27899) base compared with five other compounds tested against 392 
strains of gram-positive organisms. 
MIC (p. . /ml)  
~ 
Organism (no. tested) Antimicrobial agent 50% 90% Range 
Staphylococcus aureus 
oxacillin-susceptible (50) 
oxacillin-resistant (25) 
Staphylococcus epidermidis (25)” 
staphylococcus haemofyticus 
Coagulase-negative staphylococci (38)‘ 
Enterococcus faecalis (32) 
Enterococcus faecium (30) 
Enferococcus spp., other (20) 
Everninomycin 
Vancomycin 
Teicoplanin 
Chloramphenicol 
Clinafloxacin 
Doxycycline 
Everninomycin 
Vancomycin 
Teicoplanin 
Chloramphenicol 
Clinafloxacin 
Doxycycline 
Everninomycin 
Vancomycin 
Teicoplanin 
Chloramphenicol 
Clinafloxacin 
Doxyc ycline 
Everninomycin 
Vancomycin 
Teicoplanin 
Chloramphenicol 
Clinafloxacin 
Doxycycline 
Everninomycin 
Vancomycin 
Teicoplanin 
Chloramphenicol 
Clinafloxacin 
Doxycycline 
Everninomycin 
Vancomycin 
Teicoplanin 
Chloramphenicol 
Clinafloxacin 
Doxycycline 
Everninomycin 
Vancomycin 
Teicoplanin 
Chloramphenicol 
Clinafloxacin 
Doxycycline 
Everninomycin 
Vancomycin 
Teicoplanin 
Chloramphenicol 
Clinafloxacin 
Doxycycline 
0.12 
0.5 
0.12 
8 
10.03 
10 .5  
0.12 
0.5 
0.12 
16 
0.12 
1 0.5 
0.25 
1 
0.5 
16 
50.03 
50.5 
0.25 
1 
1 
4 
10.03 
10.5 
0.25 
0.5 
0.25 
8 
50.03 
10 .5  
0.25 
2 
0.12 
8 
0.12 
10.5 
0.25 
1 
0.25 
8 
0.5 
50.5 
0.25 
0.5 
0.12 
8 
0.12 
0.5 
0.25 
0.5 
0.25 
8 
10.03 
10.5 
0.25 
0.5 
0.25 
16 
1 
4 
0.5 
1 
0.5 
16 
0.25 
1 
0.5 
2 
16 
16 
0.5 
2 
0.5 
1 
1 
>16 
0.25 
8 
0.25 
0.25 
16 
2 
8 
0.25 
64 
16 
8 
16 
0.5 
8 
0.25 
8 
0.25 
>16 
>64 
>64 
50.015-0.25 
0.25-0.5 
0.06-0.5 
4->16 
10.03-0.12 
10.5-4 
0.12-0.25 
0.5 
0.12-0.5 
8-16 
10.03-2 
10.5-4 
0.12-0.5 
0.5-1 
0.12-1 
8->16 
10.03-0.25 
10.5-16 
0.06-0.5 
0.12-2 
0.12-16 
2-16 
10.03-0.5 
50.5-8 
0.12-1 
0.25-1 
0.06-4 
4->16 
10.03-0.5 
10.5-16 
0.12-0.5 
0.5->64 
0.06->64 
8->16 
0.06-2 
1 0.5-> 16 
0.12-0.5 
0.25->64 
0.06->64 
4->16 
0.06->8 
<0.5->16 
50.015-0.5 
10.03-8 
10.03-0.25 
4-16 
10.03-8 
10.5->16 
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Table 2 continued. 
MIC (pf/ml) 
Organism (no. tested) Antimicrobial agent 50% 90% Range 
Streptococcus spp. 
serogroup A (25) Everninomycin 0.06 0.06 0.03-0.12 
Vancomycin 0.25 0.5 0.25-0.5 
Teicoplanin 0.12 0 25 0.12-0.2s 
serogroup B (25) 
serogroups C,F, and G (15) 
viridans gr. (25) 
pneumonine (54)d 
Bacillus cereus (7) 
Corynebacterium jeikeium (1 1) 
Everninomycin 0.06 
Vancomycin 0.2s 
Teicoplanin 0.06 
Chloramphenicol 2 
Clinafloxacin 0.06 
Doxycycline 8 
0.12 0.06-0.12 
0.25 0.25 
50.03-0.12 0.06 
4 2-4 
0.06 5 0.03-0.12 
16 50.5-16 
Everninomycin 0.06 0.12 0.06-0.12 
Vancomycin 0.5 0.5 0.25-0.5 
0.06-0.25 Teicoplanin 0.12 0.25 
Everninomycin 0.12 0.25 0.06-0.5 
Vancomycin 0.25 0.25 0.25 
Teicoplanin 0.12 0.25 0.12-0.5 
Everninomycin 
Vancomycin 
Teicoplanin 
0.06 
0.25 
0.25 
Everninomycin 0.12 
Teicoplanin 0.12 
Chloramphenicol 4 
Clinafloxacin 10.03 
Doxycycline 50.5 
Vancomycin 0.5 
0.06 0.03-0.06 
0.5 0.25-0.5 
0.25 0.12-0.25 
0.12-0.25 
0.25-1 
5 0.03-0.12 
4 
5 0.03 
50.5 
Everninomycin 0.12 0.12 0.03-0.25 
Teicoplanin 0.5 0.5 0.5-1 
Vancomycin 0.5 0.5 0.5 
a. Seventeen strains were oxacillin-resistant. 
b. Five strains were oxacillin-resistant. 
c. Fifteen strains were oxacillin-resistant 
d. Includes 12 penicillin-resistant strains (penicillin MICs 2 0.1 2 pg/ml). 
clinafloxacin = vancomycin (ratio = 2) > doxycycline 
(ratio = 0.25). 
MICs of everninomycin and vancomycin were 
determined for 10 Enterobacteriaceae strains, 17 strains of 
other gram-negative non-enteric bacilli, and 15 strains 
of anaerobic organisms (data not shown). Ever- 
ninomycin like vancomycin, usually failed to show 
antimicrobial activity against gram-negative organisms 
(MICs > 32 pg/ml) with a notable exception. Vanco- 
mycin (14) and everninomycin both had measurable 
activity ( M I & , :  2 pg/ml) when tested against eight 
strains of Flavobacterium meningosepticum (1 5). We 
detected no activity for everninomycin against B.jagilis 
(MICs > 32 pg/ml), unlike that antimicrobial activity 
of everninomycin B against B. fragilis reported by 
Sanders and Sanders (8). These investigators also 
reported good potency for everninomycin B against 
Clostridium spp. and our results confirm theirs (MICs 
0.06 to 0.5 pg/ml). Furthermore, everninomycin was 
very active against Peptostreptococcus spp. (MICs I 0.015 
to 0.06 pg/ml) and had variable activity against 
Prevotella bivia-disiens (five of six strains with MICs I 2 
Numerous procedure alterations to the NCCLS in 
vitro testing methods were made and the effects on the 
everninomycin antimicrobial activity are listed in Table 
3. Modest changes (I one log2 dilution step variation) 
for the six species were observed after decreasing (lo3 
CFU/spot) or increasing ( lo5 CFU/spot) the standard 
inoculum concentration, increasing the magnesium 
concentration (100 mg/l), or increasing the pH to 8. 
Everninomycin activity was markedly diminished 
F d m l ) .  
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Figure 2 Kill curve for S. aureus ATCC 29213 at everninomycin base concentrations of 0.5 pg/ml (MIC), 1 pg/ml (two-fold the 
MIC), and 4 pg/ml (eight-fold the MIC). 
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Figure 3 Kill curve for a total of four gram-positive cocci tested at 4 pg/ml everninomycin base (eight- to 16-fold the MIC). 
MR = methicillin-resistant and MS = methicillin-susceptible (MIC s 8 pg/ml). 
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Table 3 Effect of method, inoculum concentrations, supplements, pH, and type of incubation on the MlCs (pg/rnl) of 
everninomycin (SCH 27899) base tested against six selected groups of gram-positive organisms (24 strains). 
Inoculum conc. (CFU/Spot)  Supplement a PH Incubation ' I  
O p n i s m  (no. tested) I@ lo4 lo5 lo6 5%SBC Mg 6.0 8.0 5% C 0 2  ANA 
Stapliylomcial aurcns, 
oxacillin-susc. (4) 0.06' 0.00 0.12 0.25 0.25 0.06 10.015 0.12 0.06 0.03 
Stapliyloroorial aureus, 
Staphylororcal epidrrmidic, 
oxacillin-resist. (4) 0.06 0.12 0.12 0.25 0.5 0.12 0.03 0.12 0.06 0.03 
oxacillin-susc. (4) 0.06 0.06 0.12 0.5 0.5 0.06 0.06 0.12 0.06 0.06 
Stapliylocoiial Iiaeniolytior~~s~ (4) 0.12 0.25 0.25 0.5 0.5 0.12 0.06 0.12 0.06 0.06 
G~iteroioiiw~faeialis (4) 0.06 0.12 0.12 0.25 1 0.06 0.03 0.12 0.06 0.06 
Enterotoiius fartiurn (4) 0.06 0.06 0.12 0.25 0.5 0.06 50.015 0.12 0.06 0.06 
a. SBC = sheep blood cells and Mg = magnesium concentration of 100 Fg/ml 
b. ANA = anaerobic incubation environment. 
c. Cited result represents median among four strains of each species. 
d. Three oxacillin-resistant strains. 
Table 4 Comparison of everninomycin (SCH 27899) 
formulation MlCs performed on agar or in broth for five 
organism species (24 strains).a 
Agar MlC/b ro th  MIC ratio 
Everninomycin   fir mu la ti on 
(no. tested) 0.2.5 0.5 1 2 
Base (24) 5 14 5 0 
NMG (24) 0 15 8 1 
NMG HPPCD (24) 0 16 7 1 
a .  Includes four strains each of S. a u r e ~ s  (oxacillin-susceptible), 
S. a u r r 7 ~ ~  (oxacillin-resistant), S. epidermidis, S. haemolytiius, G. 
j~eca l i c  and E. &&rn. 
(> three log2 dilution steps) by increasing the inoculum 
to lo6 CFU/spot and by adding 5% sheep blood to the 
agar. Everninomycin activity was enhanced by 
incubating the samples in 5-7% C02 (also see acid pH) 
or under anaerobic conditions. This differs from some 
earlier reports where no effect on the activity of ever- 
ninoniycin B and D was observed when incubated in 
air, 10% COz, or anaerobically; but decreased activity 
did occur as the inoculum density was elevated (8-10). 
A comparison of the antibacterial activity of the 
three formulations (base, NMG, NMG and HPPCD) 
of everninomycin was performed using an agar 
MIC/broth MIC ratio (Table 4). The ratios show an 
increase (mode ratio: 0.5) of the activity when 
performed by the Mueller-Hinton agar dilution 
method (12). This effect was most pronounced for the 
everninomycin base preparation. 
Table 5 displays the antimicrobial activity of 
everninomycin tested against a set of fluoroquino- 
lone-resistant (24 strains), gentamicin-resistant (51 
strains), and vancomycin-resistant (56 strains) clinical 
isolates. Everninomycin demonstrated excellent activity 
( M I G O  5 0.25 pg/ml) against the fluoro-quinolone- 
resistant and gentamicin-resistant groups of organisms. 
Everninoniycin was slightly less potent but still active 
against vancomycin-resistant strains (MICio: 0.5 pg/ml 
and MIC90: 2 pg/ml). 
Table 6 lists the antimicrobial activity of evernino- 
mycin tested against gram-positive strains with defined 
types of vancomycin resistance (3, 4, 6, 12). Evernino- 
mycin base was active against all tested strains (MICs 5 
4 pg/ml). The rank order of everninoniycin activity 
(listed from highest to lowest) testing the vancomycin 
genotypic resistance groups (based on the MICso 
results) was: vunC (vancomycin-intermediate, teico- 
planin-susceptible) > vunA (vanconiycin-resistant, 
teicoplanin-resistant) = vunB (vancomycin-resistant, 
teicoplanin-susceptible) > constitutively vancomycin- 
resistant species (Leuconostoc spp., Pediococcus spp., 
Luctobucillus spp.) . 
The everninomycin MBC/MIC ratios were deter- 
mined wing ten bacteria. Three strains exhibited a 
MBC/MIC ratio of 32 or more. Another three 
organisms had MBC values equal to the everninomycin 
MIC. These results suggest that everninomycin is 
not uniformly bactericidal, a result that has been 
previously reported for other everninomycin coni- 
pounds (8-10, 14). 
Figure 2 displays the initial inoculum and sub- 
sequent concentrations (CFU/nil) of Staphylococcus 
uureus ATCC 29213 grown in the presence of various 
everninomycin concentrations ranging from the MIC 
to eight-fold the MIC. This plot was also representative 
of the kill curves for the other three gram-positive 
species tested [data not shown]. There was a concen- 
tration-related inhibition displayed over the 0.5 p g / d  
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Table 5 Antimicrobial activity of everninomycin (SCH 27899) base tested against 131 gram-positive organisms with 
resistance to various other antimicrobial agents. 
Cumulative % inhibited at everninomycin MIC (pg/m/)  OJ 
Resistant organism populationa (no. tested) 50.06 0.12 0.25 0.5 1 2 4 
Fluoroquinolone-resistant’ (24) 0 29 96 100 
Gentamicin-resistant‘ (5 1) 24 49 98 100 
Vancomycin-resistant” (56) 0 7 46 50 70 91 100 
a. Ciprofloxacin MICs > 2 @g/ml, gentamycin MICs > 4 &ml and vancomycin MICs > 4 pg/ml (12). 
b. Includes E.faecium (nine strains); E.faecalis (two strains); S. aureus, oxacillin-resistant (ten strains); S.  simulans, oxacillin-susceptible (one strain), 
S. epidermidis, oxacillin-susceptible (one strain), S. haemolyticus, oxacillin-susceptible (one strain). 
c. Includes E. f e c a l i s  (15 strains), E. faecium (nine strains), Streptococcus spp., serogroup B (19 strains), S. aureus, oxacillin-resistant (six strains), 
S. epidermidis, oxacillin-susceptible (one strain), S.  haemolyticus, oxacillin-susceptible (one strain). 
d. Includes E. faecalis, vanA (three strains), E. faecalis, uanB (seven strains), E. faecium, vanA (ten strains), E. faecium, uanB (five strains), 
E.  pllinarum, uanC (one strain), Lactobacillus spp. (ten strains, three species), Leuconostoc spp. (ten strains, five species), Pediococcus spp. (ten 
strains, three species). 
through 4 pg/ml range. There was a two login CFU 
reduction by everninomycin at eight-fold the MIC 
(4 pg/ml) detected after 24 or 48 hours. 
Figure 3 shows the kill curve results obtained for 
representives of gram-positive bacteria (four strains) 
tested at 8- to 16-fold the MIC of everninomycin. 
There was strain-to-strain variation in the reduction of 
bacterial counts at  the level of everninomycin tested 
(4 pg/ml). There was no bactericidal activity detected 
(a three loglo decrease in the initial inoculum). 
However, a one to nearly three loglo CFU decrease was 
observed at 24 hours. The everninomycin concen- 
tration tested prevented regrowth of three strains 
during the monitored 48 hour period. Previous studies 
have described bactericidal activity for everninomycin 
compounds tested against some streptococci, entero- 
cocci, and Staphylococcus spp. (8-10). 
The results cited above appear to be similar to 
previously reported results from studies of evernino- 
mycin derivatives (8-1 0). Specifically, everninomycin 
was active against all strains of gram-positive species 
tested including oxacillin-resistant S. aureus (MICs 
10.25 pg/ml), glycopeptide-resistant enterococci 
(MICs I 0.5 pg/ml), penicillin-resistant pneumococci 
(MICs I 0.06 p,g/ml), anaerobes (MICs 5 0 . 5  pg/ml), 
C. .jeikeium (MICs 10.25 pg/ml) and B. cereus (MICs, 
10.25 pg/ml). Additional everninomycin potency was 
documented against Prevotellu spp. (MIC5o: 1 pg/ml) 
and Flavobacterium meningosepticum (MIC50: 2 
Fg/ml). The latter activity may be clinically valuable 
as an alternative therapy (1 5). Neisseria gonorrhoeae 
(MIC90s: 0.015 to 0.5 pg/ml), meningococci (MICgo: 
0.25 pg/ml) and Huemophilus injuenzue (MICso: 8 pg/ 
ml) among gram-negative species were also reported to 
be susceptible to some everninomycins (8-10). 
Table 6 Activity of everninomycin base tested against 61 
strains of gram-positive bacteria (15 species) with varying 
types of vancomycin resistance. 
~~ 
Everninomycin MIC (pg /m/ )  
Organisms/genotype 
(no. tested) Range M I c s o  
Enterococcus faecalis 
vauA (3) 
vanB (7) 
Enterococcus faecium 
vanA (1 0) 
uanB (5) 
Enterococcus s p ~ . ~  
vauC (6) 
kuconostoc spp. 
Pediococcus spp. (10)‘ 
Lactobacillus spp. 
0.12-0.5 
0.12-0.25 
0.25 
0.12-0.25 
0.12-0.25 
0.25-4 
1-4 
1-2 
0.25 
0.25 
0.25 
0.25 
0.12 
1 
1 
2 
a. Includes Enterococcus cusselij7auus (three strains) and E. gallinarum 
(three strains). 
b. Includes Leueonostoc spp. (five strains), L. amblosum (one strain), L. 
citeum (one strain), L. mesenteroides (two strains) and L. pseudo- 
mesenteroides (one strain). 
c. Includes Pediococcus spp. (two strains), P acidilactici (seven strains), 
and P pentosaceus (one strain). 
d. Includes Lactobacillus casei ss. rhamnosus (eight strains), L. 
delbrueckii (one strain), and L. plantarum (one strain). 
The reference drugs tested, including the clinically 
available glycopeptides, a potent investigational fluoro- 
quinolone (1 l), and older broad-spectrum drugs (chlor- 
amphenicol, doxycycline) possess comparable or 
narrower gram-positive spectra of activity when 
compared with everninomycin. These described anti- 
microbial qualities indicate the need for continuing 
investigation on the clinical pharmaco-kinetics, toxicity 
and in vivo efficacy of everninomycin. 
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